sorafenib has been researched along with Glioma in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, QX; Cheng, J; Fan, YQ; Liu, BH; Wang, JM; Zhou, H | 1 |
| A, M; A, Z; E, L; I, W; J, JG; J, SW; W, R | 1 |
| Barbier, EL; Coquery, N; Lemasson, B; Rémy, C; Serduc, R | 1 |
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I | 1 |
| Ackerl, M; Dieckmann, K; Flechl, B; Hainfellner, J; Hassler, MR; Marosi, C; Preusser, M; Sax, C; Widhalm, G; Wöhrer, A | 1 |
| Bambury, RM; Morris, PG | 1 |
| Aigner, A; Kiprianova, I; Kögel, D; Milosch, N; Mohrenz, IV; Remy, J; Seifert, V | 1 |
| Buchfelder, M; Eyüpoglu, IY; Rauh, M; Savaskan, NE; Sehm, T; Wiendieck, K | 1 |
| Altieri, DC; Gilbert, CA; Raskett, CM; Ross, AH; Siegelin, MD | 1 |
| Demers, A; Green, MR; Li, L; Moser, RP; Ross, AH; Sheng, Z; Smith, TW; Zhu, LJ | 1 |
| Barbier, EL; Bouchet, A; Coquery, N; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Robert, P; Serduc, R; Troprès, I | 1 |
| Agarwal, S; Elmquist, WF; Ohlfest, JR; Sane, R | 1 |
| Barbier, EL; Christen, T; Duchamp, O; Farion, R; Fondraz, N; Genne, P; Lemasson, B; Provent, P; Remy, C; Segebarth, C; Tizon, X | 1 |
| Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X | 1 |
| Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR | 1 |
| Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M | 1 |
| Jane, EP; Pollack, IF; Premkumar, DR | 1 |
2 trial(s) available for sorafenib and Glioma
| Article | Year |
|---|---|
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A | 2013 |
15 other study(ies) available for sorafenib and Glioma
| Article | Year |
|---|---|
ACSL4 suppresses glioma cells proliferation via activating ferroptosis.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coenzyme A Ligases; Down-Regulation; Eicosapentaenoic Acid; Ferroptosis; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hydroxyeicosatetraenoic Acids; Male; Middle Aged; RNA, Small Interfering; Sorafenib | 2020 |
LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chromones; Glioma; Humans; Morpholines; Sorafenib; Survival Analysis; Transfection | 2021 |
Cluster versus ROI analysis to assess combined antiangiogenic therapy and radiotherapy in the F98 rat-glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Glioma; Magnetic Resonance Imaging; Male; Rats, Inbred F344; Sorafenib | 2018 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combination; Glioblastoma; Glioma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Necrosis; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib | 2014 |
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2014 |
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Topics: Activating Transcription Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Cytochromes c; Gene Knockdown Techniques; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitrophenols; Peptide Hydrolases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; STAT3 Transcription Factor; Sulfonamides; Tyrphostins | 2015 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Knockdown Techniques; Glioma; Humans; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Pyramidal Cells; Rats; Sorafenib; Temozolomide | 2016 |
Sorafenib exerts anti-glioma activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioblastoma; Glioma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Random Allocation; Sorafenib; Treatment Outcome | 2010 |
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
Topics: Activating Transcription Factors; Animals; Apoptosis; Benzenesulfonates; Brain Neoplasms; Cyclic AMP Response Element-Binding Protein; Gene Expression Profiling; Glioma; Humans; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2010 |
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Disease Models, Animal; Glioma; Heterocyclic Compounds; Macromolecular Substances; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Sorafenib | 2010 |
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Blood-Brain Barrier; Brain; Cell Line; Dogs; Glioma; Humans; Male; Mice; Mice, Knockout; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line, Tumor; Glioma; Humans; Magnetic Resonance Imaging; Male; Microvessels; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Staining and Labeling; Survival Analysis | 2011 |
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Glioma; Humans; Immunoenzyme Techniques; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; raf Kinases; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Vitamin K 1; Vitamins | 2012 |
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Immunohistochemistry; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Folding; Protein Kinase C; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2006 |